Successful use of extracorporeal membrane oxygenation in a human immunodeficiency virus infected patient with severe acute respiratory distress syndrome

Robertas Samalavicius1, Mindaugas Serpytis1,2, Donata Ringaitiene1,2, Daiva Grazulyte1, Ruta Bertasiute3,4, Bernardas Rimkus4, Raimonda Matulionyte5,6, Ruta Ambrazaitiene4, Jurate Sipylaite1,2, Tomas Kacergius8 and Laimonas Griskevicius3,4

Abstract

Introduction: We report a case of an adult patient with human immunodeficiency virus (HIV), acute respiratory distress syndrome (ARDS) and ventilator associated pneumonia (VAP) caused by multidrug resistant (MDR) bacteria that was successfully managed with veno-venous extracorporeal membrane oxygenation (ECMO).

Case report: A 25 year old male with no significant past medical history had been admitted to a local hospital due to dyspnea and fever. His pulmonary function subsequently failed necessitating mechanical ventilation (MV) and introduction of ECMO support. The patient was transported for 300 km by road on ECMO to a tertiary medical center. The diagnosis of ARDS, HIV infection and MDR bacterial and fungal VAP was made. Patient was successfully treated with antiretroviral therapy (ART), anti-infective agents and 58 days of veno-venous ECMO support, with complete resolution of the respiratory symptoms.

Conclusion: HIV infected patients with ARDS and MDR bacterial VAP whose HIV replication is controlled by ART could be successfully managed with ECMO.

Keywords: HIV, veno-venous ECMO, ARDS, multidrug resistant bacteria, VAP

Background

According to Berlin definition [1] acute respiratory distress syndrome (ARDS) is characterized by 1) lung injury of acute onset, within 1 week of an apparent clinical insult and with progression of respiratory symptoms; 2) bilateral opacities on chest imaging not explained by other pulmonary pathology (e.g. pleural effusion, pneumothorax, or nodules); 3) respiratory failure not explained by heart failure or volume overload; 4) mechanical ventilation with decreased PaO2/FiO2 (ratio of partial pressure of arterial oxygen to fraction of inspired oxygen).

Extracorporeal membrane oxygenation (ECMO) is salvage therapy for selected group of patients with gas-exchange failure refractory to mechanical ventilation (MV). Severe hypoxemia despite the application of high levels of PEEP or uncompensated hypercapnia are the main indications for ECMO treatment. Mechanical ventilation at high settings (FiO2 90%, Pplat >30 mmHg) for more than 7 days, immunosupression and intracranial hemorrhage are the main contraindications for using this mode of treatment. ECMO is associated with considerable risks for the patient, including but not limited to bleeding, infection or mechanical failure of the ECMO circuit [2]. Recently, ECMO has been shown to be very effective in treating ARDS patients during H1N1 pandemic [3] and successful use of ECMO in immunocompromised patients has been reported [4,5].
However, it remains a relative contraindication to extracorporeal life support.

The purpose of this report is to describe a human immunodeficiency virus (HIV) infected patient with ARDS complicated by multidrug resistant (MDR) bacterial and fungal ventilator associated pneumonia (VAP) who was successfully managed with veno-venous ECMO and off-label doses of antimicrobial agents.

**Case presentation**

A 25 year old male with no significant past medical history was admitted to a local hospital due to dyspnea and fever of 39°C. The patient's pulmonary computer tomography (CT) scan was consistent with alveolitis. Sputum and blood cultures were negative. Patient received empirical Amoxicillin prior to hospitalisation and Cefuroxime in hospital without any improvement. For suspected allergic alveolitis prednisolone 40 mg daily for 8 days was administered. As a result of worsening of respiratory function on day 10 of initial hospitalization, the patient was transferred to intensive care unit (ICU). 1 gram of methylprednisolone once, followed by three consecutive doses of 120 mg/day were administered. Pulmonary function deteriorated and mechanical ventilation was initiated on day 6 in intensive care unit stay. No signs of any other organ system dysfunction were evident. Antibiotic therapy was changed to Imipenem and Vancomycine. On day 11 of MV, the patient’s respiratory function deteriorated substantially. The decision was made to transfer the patient to Vilnius University Hospital Santariskiu Klinikos (VUHSK) with facilities for ECMO treatment.

When transport team arrived, tidal volume was decreasing to critical levels trying to achieve safe ventilation pressures, the patient had drained pneumothorax, \( \text{PaO}_2/\text{FiO}_2 \) of 84 mmHg on 85% of \( \text{FiO}_2 \) and 16 cm \( \text{H}_2\text{O} \) of PEEP. As well patient had permissive hypercapnia with \( \text{CO}_2 \) of 87 mmHg; Murray score was 4 (up to four points in each of four categories; \( \text{PaO}_2/\text{FiO}_2 \), number of quadrants with alveolar consolidation, PEEP, and compliance) [6]; pulmonary compliance was only 4 ml/cm \( \text{H}_2\text{O} \); with pressure control ventilation of 30 cm \( \text{H}_2\text{O} \) the inspired tidal volume was only 2 ml/kg. The decision was made to place the patient on veno-venous ECMO before the transfer because \( \text{PaO}_2/\text{FiO}_2 \) of less than 80 mmHg on 90% of \( \text{FiO}_2 \) and Murray score of 3–4 identifies the risk of mortality of 80% with conventional treatment and is an indication for initiation of extracorporeal life support according to the extracorporeal life support organization guidelines (www.elso.med.umich.edu/Guidelines.html). 23 French drainage cannula (Biomedicus, Medtronic Inc., Minneapolis, USA) was inserted percutaneously into inferior vena cava via femoral approach and 19 French return cannula was inserted into the left internal jugular vein. ECMO circuit consisted of biolite coated Quadrox PLS oxygenator and Rotaflow centrifugal pump (Maquet Cardiopulmonary AG, Rastatt, Germany). The patient was uneventfully transported for 300 km (200 minutes) by road ambulance to VUHSK, ECMO flow was 6 l/min.

On admission to VUHSK, the patient’s lung compliance was 3–4 ml/cm \( \text{H}_2\text{O} \), his respiratory tidal volume was only 1–2 ml/kg to keep the ventilation pressure safe at <30 cm \( \text{H}_2\text{O} \). The patient had lung infiltration of

![Figure 1 Chest x-ray on admission at VUHSK (3 hours after ECMO start).](http://www.aidsrestherapy.com/content/11/1/37)
| ICU day | Acinetobacter baumannii | Pseudomonas aeruginosa** | Pseudomonas fluorescens | Enterobacter aerogenes | Bacteria | Fungus | Virus | CRP, mg/L | Treatment | MIC, mg/L | Administration route | Daily dose |
|---------|-------------------------|--------------------------|------------------------|-----------------------|----------|--------|-------|---------|-----------|-----------|----------------------|------------|
| 1       | BAL/CAT                 | BAL/CAT                 | BAL/BL                | BAL/BL                | 93       | Colistin | C. parapsilosis | Cytomegalovirus (CMV) | 1         | i.v.         | 13.5 m. IU          | 13.5 ml. IU |
| 3       | SP                      | BAL                     | BAL/BL                | BAL/BL                | 165      | Colistin | 0.125 | i.v. | 0.8 g |
| 8       | BAL                     | BAL                     | BAL                   | BAL/BL                | 77       | Anidulafungin | C. glabrata | C. parapsilosis | 3         | i.v. | 0.1 g |
| 11      | BAL                     | BAL                     | BAL/BL                | BAL/BL                | 151      | Colistin | 0.5   | i.v. | 1.2 g |
| 16      | BAL                     | BAL                     | BAL/BL                | BAL/BL                | 286      | Ciprofloxacin | 0.5   | i.v. | 2.4 g |
| 24      | BAL/BL                 | BAL/BL                 | BAL/BL                | BAL/BL                | 22       | Ciprofloxacin | 0.5   | i.v. | 1.2 g |
| 28, 35, 39 | BAL/UR            | BAL/UR                 | BAL/UR                | BAL/UR                | 286      | Ciprofloxacin | 0.5   | i.v. | 13.5/9 m. IU |
| 43      | BAL/UR                 | BAL/UR                 | BAL/UR                | BAL/UR                | 98       | Cefepim | 0.5   | i.v. | 6 g |
| 51      | BAL                     | BAL                     | BAL                   | BAL/BL                | 86       | Colistin | 0.5   | i.v./inh | 13.5/15 m. IU |
| 65, 70  | BAL                     | BAL                     | BAL/UR                | BAL/UR                | 73       | Amphotericin B | 0.5   | i.v. | 0.8 g |
| 75      | CAT                     | CAT                     | CAT                   | CAT                   | 90       | Ciprofloxacin | 0.38  | i.v. | 2.4 g |
| 77      | CAT                     | CAT                     | CAT                   | CAT                   | 108      | Imipenem | <0.25 | i.v. | 3 g |

ICU – intensive care unit, CRP – C-reactive protein, MIC – minimal inhibitory concentration, BL – blood, BAL – bronchoalveolar lavage, CAT – catheter, UR – urine, i.v. – intravenous, inh.-inhaled, m. – million, IU – international units.

*Acinetobacter baumannii was carbapenems (Imipenem, Meropenem MIC 32 mg/L), aminoglycoside (Amikacin MIC 256 mg/L, Gentamycin MIC 24 mg/L) and cephalosporin (Cefepim MIC 48 mg/L) resistant;

**Pseudomonas aeruginosa was carbapenems (Meropenem MIC 32 mg/L), cephalosporin (Cefepim MIC 12 mg/L) resistant.
4 quadrants seen on chest x-ray (Figure 1). The white blood cell (WBC) count was \(8.72 \times 10^9\)/L (neutrophils \(7.71 \times 10^9\)/L, lymphocytes \(0.66 \times 10^9\)/L), platelets \(257 \times 10^9\)/L, hemoglobin 109 g/l, lactate 1.36 mmol/L and C-reactive protein (CRP) was 93 mg/L. On the first day at VUHSK, the patient was confirmed HIV positive (positive anti-HIV ½ Ag/Ab, Western Blot analysis showed three bands (p41, gp120 and p51) and HIV-1 RNA was 2.22 million copies/mL), his CD4 cell count was 134 cells/\(\mu\)L. The blood sample was positive for CMV DNA (442420 copies/mL). The bronchoalveolar lavage (BAL) fluid WBC count was 1.17 \(\times\) 10^9/L (99% neutrophils) and was positive for CMV DNA (76740 copies/mL), Candida glabrata and MDR Acinetobacter baumanii. The diagnosis of ARDS, HIV infection, nosocomial VAP and possible CMV pneumonitis was made. Colistin, Linezolid, Imipenem, Ganciclovir and Anidulafungin were started. ART consisting of Kivexa (Abacavir and Lamivudine) and Kaletra (Lopinavir and Ritonavir) was initiated. The patient was continued with MV, full intensive care and intermittent vasopressor support. Blood flow during ECMO was tailored to achieve acceptable oxygenation. Ventilator settings were reduced to protective ventilation mode. During the ICU stay, aggressive treatment of numerous nosocomial infections was required (Table 1). Complications during ECMO are detailed in Table 2.

Despite aggressive treatment, improvement of pulmonary mechanics was slow (tidal volume with \(P_{peak}\) 30 cm H\(_2\)O was only up to 2 ml/kg, compliance remained at 1–4 ml/cm H\(_2\)O). For the downregulation of immune reconstitution inflammatory syndrome, intravenous methylprednisolone 1 mg/kg/dose per day for 7 days was administered on ECMO day 18 and then gradually tapered off over 15 days. This resulted in improved lung function (tidal volume increased to 4.4 ml/kg with \(P_{peak}\) 27 cmH\(_2\)O and compliance 9–10 ml/cm H\(_2\)O).

The first oxygenator was exchanged on day 38 after decrease in function. The patient was weaned off ECMO.

### Table 2 Complications and their treatment during ECMO

| ICU day | Complications                                         | Treatment/Procedures                                |
|--------|-------------------------------------------------------|-----------------------------------------------------|
| 1-59   | Bilateral pneumothorax                                | Pleural cavity drainage                             |
| 25, 31, 51 | Pulmonary hemorrhage                                      | Endobronchial hemostasis                               |
| 38     | Tilt of left jugular vein cannula with blood loss of 2 liters | Cannula reinserted, transfusions of packed red blood cells and platelets |
| 46     | Blood-clot masses in pleural cavity                  | Open right side thoracotomy with clot removal and lung decortication |
| 48     | Left side tension pneumothorax with cardiogenic shock | Pleural cavity drainage, resuscitation               |
| 52     | Bleeding from tracheostoma                            | Endobronchial hemostasis                             |
| 60     | Cannula associated deep vein thrombosis               | Bronchoscopy and clot-mass removal                    |
|        | Endobronchial clot-masses                              | Heparin, compression therapy                         |

![Figure 2](http://www.aidsrestherapy.com/content/11/1/37)
after 56 days. Unfortunately, 48 hours later, acute hypercapnic respiratory failure developed (pCO2 190 mmHg, pH 7.05). The veno-venous ECMO was re instituted with successful weaning after 48 hours. MV was continued for additional 18 days.

After 70 days of ART, the patient’s CD4 cell count increased to 268 cells/µL and the HIV-1 viral load became 591 copies/mL, lung chest X-ray is shown in Figure 2. The patient was transferred to a general ward and later discharged from hospital to continue rehabilitation. At the last clinic visit 115 days after having been discharged from ICU, the patient reported good health, had no pulmonary symptoms, could walk unassisted for more than 2 kilometers.

In total, 51 packed red blood cells and 14 platelet units were transfused. The total duration of ECMO was 58 days. The total MV duration was 87 days (11 pre ECMO, 58 ECMO and 18 post ECMO). The total VUHSK ICU stay was 84 days.

Discussion
ECMO use in immunocompromised patients is controversial because of high mortality [7-9]. To the best of our knowledge, there is only one report of ECMO use in HIV infected patient [5]. We had not been aware of the patient’s HIV infection and thus were not biased when deciding to initiate ECMO support. Also, our patient may have had an early stage of HIV infection as witnessed by a high HIV-1 viral load in parallel with a weak antibody band spectrum on Western Blot analysis and relatively rapid CD4 count recovery.

Importantly, our patient had a predominant pulmonary failure while the function of other organs was relatively preserved making veno-venous ECMO a good choice of gas-exchange support while anti-infective therapy took effect. Also, we chose an aggressive preemptive approach to diagnose and treat nosocomial superinfections. Increased cardiac output, leaky capillaries, enlarged volume of distribution and impaired tissue penetration in septic patients may lead to an inadequate concentration of antimicrobial agent at the target site [10]. Also, due to sequestration and increased volume of distribution patients on ECMO are at risk of suboptimal antimicrobial therapy [11]. Therefore, there is a tendency to use higher doses of antimicrobial agents in critically ill patients. In our case, antibiotics were changed as soon as nosocomial bacteria were identified at doses that in many cases were considerably higher (Table 1) [12-14] than indicated in the drug label. We did not observe unacceptable antibiotic related toxicity.

ART was initiated as soon as HIV positivity was confirmed. Of note, ART suppresses HIV replication and may cause immune reconstitution inflammatory syndrome [15]. We administered a short course of methylprednisolone resulting in improved lung function. A recent meta-analysis showed a possibility of reduced mortality and increased ventilator free days with steroids in ARDS [16].

Common complications during ECMO are pneumonia, sepsis and bleeding especially associated with invasive procedures [17]. In our case, pulmonary hemorrhage, bleeding from the cannulation site and pneumothorax (including one case of tension pneumothorax) were observed necessitating surgical and medical intervention (Table 2). After first weaning off ECMO we observed hypercapnic respiratory failure leading to hemodynamic instability. This emphasizes uneven pulmonary gas exchange reconstitution with CO2 exchange recovery often trailing that of O2 [18].

Conclusions
In individual cases, ECMO could be successfully applied in HIV infected patients with ARDS refractory to conventional treatment and ventilator-associated pneumonia caused by multidrug resistant bacteria whose HIV replication is controlled by antiretroviral therapy. Long-distance transportation on ECMO may be attempted in selected cases.

Consent
Written informed consent was obtained from the patient for publication of this Case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Abbreviations
ARDS: Acute respiratory distress syndrome; ART: Antiretroviral therapy; BAL: Bronchoalveolar lavage; CMV: Cytomegalovirus; CRP: C reactive protein; CT: Computer tomography; DNA: Deoxyribonucleic acid; ECMO: Extracorporeal membrane oxygenation; HIV: Human immunodeficiency virus; ICU: Intensive care unit; IRIS: Immune reconstitution inflammatory syndrome; MDR: Multidrug resistant; MV: Mechanical ventilation; PEEP: Positive end-expiratory pressure; RNA: Ribonucleic acid; VAP: Ventilator associated pneumonia; VUHSK: Vilnius University Hospital Santariskiu Klinikos; WBC: White blood cell.

Competing interests
All the authors declare that there are no known conflicts of interest associated with this publication and there has been no financial support for this work that could have influenced its outcome.

Authors’ contributions
RS and MS were leading members of ECMO team and were responsible for ECMO care during treatment in ICU. DR: DG and JS – preeminent reanimatologists who were responsible for main treatment during patients stay in ICU. RB: BR – were responsible for data collection, analysis and drafting the manuscript. RM – infectologist, responsible for ART and further patients’ HIV status monitoring. RA: TK – clinical microbiologist, responsible for blood, bronchial BAL: urine and catheter culture analysis, tracking the sensitivity of antibiotics and MIC’s. LG – principal investigator, manuscript revisor. All authors read and approved the final manuscript.

Author details
1Center of Anaesthesiology, Intensive Care and Pain Management, Vilnius University Hospital Santariskiu Klinikos, Vilnius, Lithuania. 2Clinics of Anaesthesiology and Intensive Care, Faculty of Medicine, Vilnius University,
Vilnius, Lithuania. 4Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santariskiu Klinikos, Vilnius, Lithuania. 5Clinics of Internal, Family Medicine and Oncology, Faculty of Medicine, Vilnius University, Vilnius, Lithuania. 6Department of Infectious, Chest diseases, Dermatovenerology and Allergology, Faculty of Medicine, Vilnius University, Vilnius, Lithuania. 7Center of Infectious Diseases, Vilnius University Hospital Santariskiu Klinikos, Vilnius, Lithuania. 8Center of Laboratory Medicine, Vilnius University Hospital Santariskiu Klinikos, Vilnius, Lithuania. 9Department of Physiology, Biochemistry, Microbiology and Laboratory Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.

Received: 21 June 2014 Accepted: 8 November 2014
Published: 21 November 2014

References
1. Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camporota L, Slutsky AS. Acute respiratory distress syndrome: the Berlin Definition. JAMA 2012, 307:2526–2533.
2. Peek CJ, Mugford M, Tiriwopiati R, Wilson A, Allen E, Thalanany MM, Hibbert CL, Truesdale A, Clemens F, Cooper N, Firmin RK, Elbourne D. Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. Lancet 2009, 374:1351–1363.
3. Australia, New Zealand Extracorporeal Membrane Oxygenation Influenza I, Davies A, Jones D, Bailey M, Beca J, Bellomo R, Blackwell N, Forrest P, Gattas D, Granger E, Herkes R, Jackson A, McGuinness S, Nair P, Pellegrino V, Pettia V, Plunkett B, Pye R, Torsillo P, Webb S, Wilson M, Ziegenfuss M. Extracorporeal Membrane Oxygenation for 2009 Influenza A(H1N1) Acute Respiratory Distress Syndrome. JAMA 2009, 302:1888–1895.
4. Liao W, Tsai SH, Chiu SK. Successful use of extracorporeal membrane oxygenation in a hematopoietic stem cell transplant patient with idiopathic pneumonia syndrome. Respir Care 2013, 58:e6–e10.
5. Gutermann H, van Roy B, Meerseman W, Meyns B, Herijgers P. Successful extracorporeal lung assistance for overwhelming pneumonia in a patient with undiagnosed full blown aids—a controversial therapy in HIV-patients. Thorac Cardiovasc Surg 2005, 53:252–254.
6. Murray JF, Matthay MA, Luce JM, Flick MR. An expanded definition of the adult respiratory distress syndrome, Am Rev Respir Dis 1988, 138:720–723.
7. van Lelyveld SF, Wind CM, Mudrikova T, van Leeuwen HJ, de Lange DW, Hoepelman AI. Short- and long-term outcome of HIV-infected patients admitted to the intensive care unit, Eur J Clin Microbiol Infect Dis 2011, 30:1085–1093.
8. Schmidt M, Zoghieb E, Roze H, Repesse X, Lebretton G, Luyt CE, Trouillet JL, Brechot N, Nieszkowska A, Dupont H, Quariza A, Leprince P, Chaubre J, Combes A. The PRESERVÉ mortality risk score and analysis of long-term outcomes after extracorporeal membrane oxygenation for severe adult respiratory distress syndrome. Intensive Care Med 2013, 39:1704–1713.
9. Hermans G, Meerseman W, Wilmer A, Meyns B, Bobbaers H. Extracorporeal membrane oxygenation: experience in an adult medical ICU. Thorac Cardiovasc Surg 2007, 55:223–228.
10. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 2009, 37:840–851. quiz 859.
11. Shekar K, Roberts JA, Ghassabian S, Mullany DW, Wallis SC, Smith MT, Fraser JF. Altered antibiotic pharmacokinetics during extracorporeal membrane oxygenation: cause for concern? J Antimicrob Chemother 2013, 68:726–727.
12. Vicari G, Bauer SR, Neuner EA, Lam SW. Association between colistin dose and microbiologic outcomes in patients with multidrug-resistant gram-negative bacteremia. Clin Infect Dis 2013, 56:398–404.
13. Michalopoulos AS, Falagas ME. Colistin: recent data on pharmacodynamics properties and clinical efficacy in critically ill patients. Crit Care Resusc 2011, 13:03.
14. Falagas ME, Rafaillidis PI, Ioannidou E, Alexiou VG, Matthaiou DK, Karageorgopoulou DE, Kapaskelis A, Nikita D, Michalopoulos A. Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrob Agents 2010, 35:194–199.
15. Akgun KM, Pisani M, Crotthers K. The changing epidemiology of HIV-infected patients in the intensive care unit. J Intensive Care Med 2011, 26:151–164.